

Emergence of Neoteric Serotypes Among Multidrug Resistant Strains of *Streptococcus pneumoniae* Prevalent in Egypt

Rehab H Bahy,¹ Hayam M Hamouda,¹ Amal S Shahat,² Aymen S Yassin,^{3,*} and Magdy A Amin³

¹Department of Microbiology, National Organization for Drug Control and Research, Giza, Egypt

²Department of Biochemistry, National Organization for Drug Control and Research (NODCAR), Giza, Egypt

³Department of Microbiology and Immunology, Faculty of Pharmacy, Cairo University, Cairo, Egypt

*Corresponding author: Aymen S Yassin, Department of Microbiology and Immunology, Faculty of Pharmacy, Cairo University, Cairo, Egypt. Tel: +20-1009610341, Fax: +20-23620122. E-mail: aymen.yassin@pharma.cu.edu.eg

Received 2015 June 11; Revised 2016 January 25; Accepted 2016 February 13.

Abstract

Background: *Streptococcus pneumoniae* is still one of the major causes of morbidity and mortality worldwide. The prevalent serotype distribution had shown variation along different studies conducted at different time intervals. In order to efficiently assess the epidemiology of the diseases for effective preventive and treatment strategies, serotype prevalence need to be periodically reassessed.

Objectives: Conducting a reassessment of the prevalent *S. pneumoniae* serotypes in Egypt as an essential step in the search for a regional vaccine. In addition, monitoring the antibiotic susceptibility patterns of pneumococcal strains currently causing infections as an evaluation of therapeutic strategies applied.

Materials and Methods: A total of 100 specimens of different sources were collected in Cairo, Egypt, from 2011 to 2013, representing almost all different types of diseases caused by *S. pneumoniae* such as meningitis, pneumonia, otitis media and sinusitis. Conventional and molecular identification methods were performed, the antimicrobial susceptibility patterns were assessed and serotyping was done using PCR assays to identify the most prevalent types. In addition, detection of certain virulence genes for the most prevalent serotypes was carried out.

Results: Our results revealed that in Egypt, currently, the most prevalent serotypes were serogroup 6 and serotype 19F as they represented 58% of all isolates. High rates of resistance were found to different antibiotic classes. The *lytA* and *psaA* genes were found to be more sensitive for *S. pneumoniae* identification than *ply*.

Conclusions: Our study illustrates the importance of constantly monitoring the prevalent serotypes in any region in order to aid in the development of more effective vaccines.

Keywords: Antibiotic Resistance, Serotyping, Virulence, Bacterial Vaccines, *Streptococcus pneumoniae*

1. Background

Streptococcus pneumoniae is a major cause of invasive diseases such as meningitis, septicemia and pneumonia. Approximately one million children under five years of age die of pneumococcal disease annually. In addition, the morbidity by *S. pneumoniae* through respiratory tract infections such as otitis media and sinusitis is enormous. Almost 30% to 50% of all patients with otitis media and a substantial percentage of cases of sinusitis and pneumonia are caused by pneumococci. Risk groups for serious pneumococcal disease include children under the age of two years, elderly and patients with immunodeficiencies (1).

The prevalent serotype distribution had been investigated in Egypt through two surveillance studies, the first one of them was conducted in a network of hospitals across Egypt, during a five-year year period (1998 - 2003)

(2). The second study was a laboratory-based surveillance of patients with bacterial meningitis (1998 - 2004). Both studies were concerned with the pneumococcal meningitis only and other types of pneumococcal diseases were not addressed (3). The pneumococcal isolates were serotyped using latex agglutination and the Quellung reaction for confirmation and in both studies, serotypes 6B, 1, 19A, 23F and 6A were the most prevalent in Egypt (2, 4).

The high cost of antisera, subjectivity in interpretation, and technical expertise requirements associated with serologic methods for *S. pneumoniae* serotyping have resulted in the development of PCR-based serotyping systems. PCR-based serotyping has the potential to overcome some of the difficulties associated with serologic testing and assays for direct detection of serotypes from clinical specimens and is a valuable aid in surveillance, particularly in situations where culture is negative (5-12).

Three pneumococcal conjugated vaccines are regis-

tered in Egypt: PCV7, which is also licensed in more than 100 countries, including the United States; it has the serotypes (4,6B, 9V, 14, 18C, 19F, 23F). PCV10, which is also licensed in Canada and Europe but not in the United States; it includes the serotypes (1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23), and PCV13, which includes serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F).

Antimicrobial resistance among *S. pneumoniae* isolates poses a special challenge for the treatment and control of pneumococcal infections, as there is an increase in the pattern of resistance over time. In Egypt, the penicillin resistance has changed over time. In 1993, 71% of the *S. pneumoniae* isolates were penicillin susceptible (13), decreasing to 63% in 2,000 and to 51% in 2004, when the drug of choice was ceftriaxone (4). Ceftriaxone susceptibility among *S. pneumoniae* isolates at this point in time was greater than 94% (4). The changes in susceptibility patterns over time suggest that the periodic monitoring of the patterns of antimicrobial resistance is necessary to guide effective treatment (14, 15).

2. Objectives

As the last study in Egypt to assess the serotypes' distribution and antimicrobial susceptibility was conducted over 10 years ago, more recent data are needed to form a comprehensive and updated understanding of serotype distribution and antimicrobial susceptibility pattern in the region for effective preventive and treatment strategies. The goal of this study is to conduct a reassessment of the prevalent serotypes in Egypt as an essential step in the search for a regional vaccine. In addition, another goal is to monitor the antibiotic susceptibility patterns of pneumococcal strains currently causing infections to evaluate the strategies applied in therapy.

3. Materials and Methods

3.1. Statement of Ethical Approval

All experiments involving any samples taken from patients in this study were conducted in accordance with and approval of the ethical committee at Cairo University, Cairo, Egypt. In addition, all patients who contributed any samples (swabs or any other form), provided written informed consent; in cases of children, written consent from the guardian or parent was obtained.

3.2. Samples Collection

A total of 100 clinical specimens were collected, in the greater Cairo area in Egypt, from 2011 to 2013. Greater Cairo area is an area of area: 1,709 km² and represents Cairo

Governorate, Giza city, Shubra El-Kheima, 6th of October city and Obour city, with a total population estimated at 20,500,000. Pneumonia represented 47% of cases, sinusitis cases were 28%, meningitis were 16%, 7% of cases were otitis media and 2% were conjunctivitis. Both conventional and molecular identification methods were applied to confirm the identification of *S. pneumoniae*.

3.3. Conventional Identification

All tests for the identification of bacteria were done according to laboratory methods for the diagnosis of meningitis (16), including: microscopical examination, and tests for optochin sensitivity (reagent; ethylhydrocupreine hydrochloride, Oxoid, UK), and bile solubility (reagent; Sodium deoxycholate, SigmaAldrich, USA).

3.4. Molecular Identification of *S. pneumoniae* Using *cpsA* Gene Using PCR Assay

For all PCR reactions, DNA was extracted using EZ-10 spin column genomic DNA miniprep kit according to manufacturer's protocol (BioBasic Inc., Canada). The *cpsA* gene was used as specific marker for the discrimination of *S. pneumoniae* from other streptococci (17). For PCR reaction, primers used were *cpsA* forward primer: 5'-GCAGTACAGCAGTTTGTGGACTG ACC-3' and *cpsA* reverse primer: 5'-GAATATTTTCATTATCAGTCCCAGTC-3'. Both primers would amplify the region corresponding to nucleotides 2,314 - 2,473. All PCR reagents and buffers were from Alliance Bio, USA. PCR thermal cycling was done at initial denaturation temperature of 94°C for four minutes, followed by 30 amplification cycles of denaturation at 94°C for 45s, annealing at 54°C for 45s and polymerization at 65°C for two minutes, 30 seconds, then final extension at 72°C for 10 minutes (12). DNA was extracted from the reference strain *S. pneumoniae* ATCC 49619 under the exact same conditions and used as a positive control.

3.5. Antimicrobial Susceptibility of *Streptococcus pneumoniae* Isolates

The tested isolates were sub-cultured on blood-agar plates and incubated in 5% CO₂ at 37°C for 24 hours. Direct colony suspension was prepared equivalent to 0.5 McFarland and used on Muller Hinton agar; then, the antibiotic discs Oxoid, UK were applied aseptically. The plates were incubated at 37°C for 24 hand the diameters of inhibition zones were measured. Isolates were classified as susceptible, intermediate or resistant in accordance with the Clinical and Laboratory Standards Institute (18). A list of antibiotics used and their concentrations is in Table 1.

Table 1. List of Antibiotics Used and Their Concentrations

Antibiotic of Different Class	Symbol	Disc Content, µg
Penicillin		
Oxacillin	OXA	1
Amox/clavulanic	AMC	20/10
Glycopeptides		
Vancomycin	VAN	30
Macrolides		
Erythromycin	ERY	15
Azithromycin	AZM	15
Clarithromycin	CLR	15
Tetracycline		
Tetracycline	TET	30
Quinolones		
Ciprofloxacin	CIP	5
Levofloxacin	LVX	5
Ofloxacin	OFX	5
Norfloxacin	NOR	10
Sulphonamides and Trimethoprim		
Sulphonamides and Trimethoprim	SXT	23.75/1.25
Amphenicols		
Chloroamphenicol	CHL	30
Aminoglycosides		
Tobramycin	TOB	10
Amikacin	AMK	30
Gentamicin	GEN	10
β-lactams/Cephalosporin, 2nd		
Cefaclor	CEC	30
Cefurxim	CXM	30
β-lactams/Cephalosporin, 3rd		
Ceftazidime	CAZ	30
β-lactams/Cephalosporin, 4th		
Cefepime	FEP	30
Cefoperazon	CFM	75
Other β-lactams		
Imepenem	IPM	10
Linezolid		
Linezolid	LZM	30

3.6. Serotyping of *S. pneumonia* Isolates Using PCR Assay:

Nine primer pairs were used to target serotypes 1, 5, 6A/B, 14, 16F, 19A, 19F, 20 and 23F (Table 2) (12). The primers

target the following genes (serotypes are indicated in parentheses): *cap1H* (1), *wxy* (5), *wcip* (6), *cps14H* (14), *cps19aK* (19A), *cps19fl* (19F), and *cps23fG* (23F). All primers were synthesized at Sigma-Aldrich, USA. All samples confirmed to have *cpsA* gene were examined to be one of the serotypes listed. The same conditions used before with the *cpsA* gene in thermal cycling were applied here.

3.7. Detection of Virulence Factors for the Identified Most Prevalent Serotypes

3.7.1. Detection of the pneumolysin (*ply*) Gene and the autolysin (*lytA*) Gene

PCR assay used to detect *pneumolysin* (*ply*) gene and the *autolysin* (*lytA*) gene was performed as previously described (19): primers used were *ply* forward outer primer, (5'-TTTCTGTAACAGCTACCAACGA-3') and *ply* reverse outer primer (5'-GAATCCCTGTCTTTCAAAGTC-3'), both primers amplified a 348-bp region of the *ply* gene, (20, 21). For the (*lytA*) gene, forward primer (5'-ACGCAATCTAGCAGATGAAGC) and reverse primer (5'-TGTTTGGTTGGTTATTCGTGC), (22), were used to amplify a 101-bp fragment of the *lytA* gene. PCR thermal cycling was performed with initial denaturation temperature at 95°C for five minutes, followed by 35 amplification cycles of denaturation at 95°C for 45 seconds, annealing at 60°C for 45 s and polymerization at 72°C for 30 seconds and final extension at 72°C for eight minutes.

3.7.2. Detection of the pneumococcal surface antigen A (*psaA*) Gene

The gene encoding the *pneumococcal surface adhesin A* (*PsaA*) protein was confirmed in all *S. pneumoniae* serotypes (18). The sequences of the primers used to amplify *psaA* were as follows: 5'CTTTCTGCAATCATTCTTG3' as the forward primer and 3'GCCTTCTTACCTTGTCTGC5' as the reverse primer (23). PCR thermal cycling was at initial denaturation temperature of 94°C for 15 minutes, followed by 30 amplification cycles of denaturation at 94°C for 30 seconds, annealing at 52°C for 30 seconds and polymerization at 72°C for two minutes and final extension at 72°C for eight minutes (24).

4. Results

4.1. Samples Collection and Conventional Identification

A total of 100 clinical specimens were collected in the greater Cairo area of Egypt, from 2011 to 2013. The samples collected represent a fair distribution across Egypt as they were collected from the main Cairo metropolitan area. Isolates were cultured and identified as *S. pneumoniae* by both conventional and molecular methods. The whole

Table 2. Oligonucleotide Primers Used in Serotyping of *S. pneumoniae* Isolates

Serotype	GenBank Accession Number	Primer Sequence (5' to 3')	Nucleotide Positions	Product Size, bp
6A/B	AF316640			250
F		AATTGTATTTTATTCATGCCATATCTGG	8656	
R		TTAGCGGAGATAATTTAAAATGATGACTA	8877	
1	Z83335			280
F		CTCTATAGAATGGAGTATATAAACTATGGTTA	10469	
R		CCAAAGAAAATACTAACATTATCACAAATTTGGC	10715	
19A	AF094575			478
F		GTTAGTCCTGTTTTAGATTATTGGTGATGT	12118	
R		GAGCAGTCAATAAGATGAGACGATAGTTAG	12566	
23F	AF057294			384
F		GTAACAGTTGCTGTAGAGGGAATTGGCTTTTC	12118	
R		CACAACACCTAACACACGATGGCTATATGATTC	12566	
14	34359			208
F		CTTGGCGCAGGTGTCAGAATCCCTCTAC	7968	
R		GCCAAAATACTGACAAAGCTAGAATATAGCC	8145	
19	U09239			304
F		GTTAAGATTGCTGATCGATAATTGATATCC	7828	
R		GTAATATGCTTTAGGGCGTTTATGGCGATAG	8100	
16F	Nr.34361			988
F		CTGTTTCAGATAGGCCATTTACAGCTTTAAATC	11521	
R		CATTCCTTTTGTATATAGTGTAGTTCATCC	12478	
20	34365			514
F		GAGCAAGAGTTTTTACCTGACAGCGAGAAG	9567	
R		CTAAATTCCTGTAATTTAGCTAAAACCTTATC	10048	
5	AY336008			362
F		ATACCTACACAACCTCTGATTATGCCTTTGTG	6123	
R		GCTCGATAAACATAATCAATATTTGAAAAAGTATG	6450	

collection of 100 isolates were identified morphologically as gram positive diplococci. Colonies of *S. pneumoniae* appeared on Blood agar plate as small, grey, moist characteristically produced a zone of alpha-hemolysis (green). Out of 100 isolates, 12 isolates were found to be optochin-resistant with inhibition zones (< 14 mm), while, only seven out of 100 isolates were bile-insoluble.

4.2. Molecular Identification of *S. pneumoniae* Using *cpsA* Gene


PCR assay for *cpsA* gene was used to identify all the 100 isolates. PCR assay revealed an amplified product in all tested samples including optochin-resistant and bile-insoluble isolates. The sizes of the amplicon obtained from the tested strains corresponded to the predicted size of 160

bp (Figure 1). A reference strain *S. pneumoniae* ATCC 49619 was used as a positive control.

4.3. Antimicrobial Susceptibility of *S. pneumoniae* Isolates

The 100 *S. pneumoniae* isolates were tested for their susceptibility to 13 antibiotics belonging to nine different classes (penicillin, glycopeptides, macrolides, tetracycline, quinolones, sulphonamides and trimethoprim, amphenicols, aminoglycosides and betalactams) by using disk diffusion method. The antibiotic resistance profiles of the isolates against the 13 antimicrobial agents are presented in Figure 2. The results revealed high resistance to different antibiotic classes, especially to penicillin (85%), tetracycline (55%) and sulphonamides and trimethoprim


Figure 1. Agarose Gel Electrophoresis of *S. pneumoniae*-Specific PCR Products Based on the *cpsA* Gene for Several Isolates



Lane 1, ladder molecular size marker; lanes 2 - 5 are representatives of *S. pneumoniae* isolates; a PCR product of 160 bp specific to *cpsA* gene is common to all isolates.

(43%), whereas, *S. pneumoniae* still have relatively high sensitivity for macrolides and quinolones (about 60% and 85% respectively).

Figure 2. The Antibiotic Resistance Profiles of the *S. pneumoniae* Isolates Against 23 Antimicrobial Agents



OXA: oxacillin, SXT: trimethoprim-sulfamethoxazole, AMK: Amikacin, CFP: cefoperazone, TET: tetracycline, TOB: tobramycin, AZM: azithromycin, ERY: erythromycin, FEP: cefepime, CLR: clarithromycin, CEC: cefaclor, CAZ: ceftazidime, VAN: vancomycin, CXM: cefuroxime, CHL: chloramphenicol, GEN: gentamicin, LZD: linezolid, CIP: ciprofloxacin, OFX: ofloxacin, LVX: levofloxacin, AMC: amoxicillin-clavulanic acid, IPM: imipenem, NOR: norfloxacin.


4.4. Serotyping of *S. Pneumoniae* Clinical Isolates

After the confirmation that each clinical isolate has capsular polysaccharide gene, another nine amplification reactions (one reaction for the identification of each serotype 1, 5, 6A/B, 14, 16F, 19A, 19F, 20 and 23F) was done to detect the specific serotype for each isolates. Isolates either were assigned to be one of the serotypes and/or serogroups tested or were designated to be “other serotype” if they failed to give a product with any of the nine serotypes primer pairs. The results of the prediction of pneumococcal serotypes revealed that the most common serotypes are 6A/B (30 %) followed by 19F (18 %). The complete distribution of the serotypes is summarized in Table 3. An example of serotyping with serotype 6A/B is shown in Figure 3.

Table 3. Serotyping Results Deduced by PCR Assay for 100 Pneumococcal Isolates

Serotype	Number of Isolates
6 A/B	30
19F	28
5	15
23F	7
Other serotypes	20

Figure 3. Agarose Gel Electrophoresis of PCR-Amplified Product of an Example of Serotyping of One Isolate Giving one Band Specific to one Serotype (6A/B)



Lane 1, DNA marker; lane 3, represents the amplified products of *cpsA* gene (160-bp fragment); lane 4, represents the amplified product of serotype 6 A/B (250-bp fragment) and lanes 5 to 12 represent amplified products of serotypes 1, 5, 14, 16F, 19A, 20, 23F and 19F respectively (all negative).

4.5. Antimicrobial Susceptibility for Predominant Serotypes


The two predominant serotypes/groups (19F serotype and 6A/B group) exhibited high rates of resistance to peni-

cillin (82% and 80%), macrolides (77% and 73%) and tetracycline (75% and 50%) respectively.

4.6. Detection of Virulence Factors for Predominant Serotypes

Detection of *pneumolysin* (*ply*) gene, *autolysin* (*lytA*) gene and the *pneumococcal surface adhesin A* (*PsaA*) protein in serotype 6A/B and serotype 19F using PCR assay revealed that, all the 58 isolates (100%) were positive for (*lytA*) and (*psaA*) genes, while only 44 out of 5 (75%) isolates were positive for (*ply*) gene, indicating that (*lytA*) and (*psaA*) genes are the most sensitive genes for detection of *S. pneumoniae*. An example is shown in Figure 4, showing the amplification product observed with *psaA* gene product with some isolates.

Figure 4. Agarose Gel Electrophoresis of PCR-Amplified Products From 6A/B and 19F Serotypes Isolates is Shown



Lane 1, DNA marker and lanes from 2 to 7, represent the amplified products for (*psaA*) gene product (838-bp fragment).

5. Discussion

In previous work investigating the spread of *S. pneumoniae*, clinical isolates were collected from CSF specimens of patients with meningitis, while few studies addressed pulmonary infection from *S. pneumoniae*. Here, we worked on several isolates from different sources, such as nose, throat, CSF, sputum and ear; therefore, it represented a more widespread approach to investigate all types of diseases caused by *S. pneumoniae* with all aspects of clinical manifestations. In addition, in this study, molecular methods were used both for detection as well as serotyping as compared to prior studies done in Egypt, which all depended on traditional biochemical tests, latex agglutination and quelling reaction.

Due to the large geographic area of the Cairo metropolis, and due to the fact that many residents even in faraway

regions all over Egypt do come to Cairo to seek treatment for severe diseases, we believe that our samples cover the distribution across the country.

Numerous studies discussed *S. pneumoniae* identification and confirmed optochin-resistance among *S. pneumoniae* isolates, making it difficult to depend on optochin-sensitivity test in *S. pneumoniae* identification (25-27). Several studies suggested that bile solubility test is more sensitive than the optochin sensitivity test (28); in agreement with these studies, we found that 12 out of 100 isolates showed optochin resistance and only 7 out of 100 isolates was found to be bile insoluble.

Molecular identification of *S. pneumoniae* using PCR assays has frequently targeted genes that encode pneumococcal virulence factors. These factors include *autolysin* (*lytA*) (22), *pneumolysin* (*ply*) (29), *pneumococcal surface antigen A* (*psaA*) (24). However, some pneumococcal virulence genes of *S. pneumoniae* have been detected in *S. mitis* or *S. oralis* isolates (19, 30, 31). Our study depends on the use of *cpsA* gene as a novel genomic marker specific for *S. pneumoniae* which is in agreement with the study done by Park et al. (17), all the clinical isolates were positively identified as *S. pneumoniae*, since they all showed the presence of this particular gene as the control reference standard strain used.

The antimicrobial susceptibility patterns were investigated using antibiotics belonging to various classes and the results indicated, in general, an increase in antibiotic resistance. Several previous studies reported penicillin resistant *S. pneumoniae* starting from Year 1991 to Year 2005, the percentage of penicillin susceptible *S. pneumoniae* dropped between the periods of 1993 - 2004. Resistance to oxacillin was only 6% in a study conducted in 1998 to 2000, while in our study, an increase in oxacillin resistance was observed as it reached 85%. Chloramphenicol resistance was variable from 29.7% in 1993, to 14% and 18% in 2000, and then dropped to 9% in 2003, then back to an increase in our current study to reach 18%. Tetracycline resistance ranged between 52% and 62%, which were almost similar to our study (57%). The same results were observed with sulphonamides and trimethoprim, which remained almost unchanged from 60% to 65% in our study (4, 13, 15, 32). However, our work is showing promising susceptibility to new antibiotics such as imipenem, with sensitivity over 96%; norfloxacin, having an 85% sensitivity, and linezolid which revealed a sensitivity of 84%.

There is a variation in the prevalent serotype amongst previous different epidemiological studies in Egypt conducted at different time intervals (2, 3, 33, 34). The first study conducted in Egypt in the late 1970s used Quellung reaction, and identified type 1 as the most frequently observed capsular type (33). The epidemiological study by

Wasfy et al. (2), between 1998 - 2003, reported that the major serotypes are (6B, 1, 19A, 23F, 6A) from CSF specimens of patients with meningitis. The other epidemiological study conducted by Afifi et al. (4), between 1998 - 2004, confirmed these finding about predominant serotypes in Egyptian patients. On the other hand, our study revealed that currently, serogroup 6 A/B and serotype 19F are the most predominant serotypes. Serotype A/B is the most prevalent with a percentage of 30%; serotype 19F represented 28% of clinical isolates and is now among the most prevalent serotypes of *S. pneumoniae*. Additionally, another new serotype (5) appeared to represent 15% of all investigated isolates, while the serotype 23F represented only 7%, indicating changes in distribution of serotypes.

Studying the virulence factors among the most prevalent serotypes (6A/B and 19F) revealed that *autolysin* and *psaA* were the most sensitive genes for identification of *S. pneumoniae* as they were detected in all 6A/B and 19F isolates (the total 58 isolates, 100 %) while pneumolysin detection had less sensitivity in *S. pneumoniae* identification as it was only detected among 44 out of the 58 isolates, 75% of the same collection as previously shown in other studies (35, 36).

In conclusion, our study showed that the most prevalent *S. pneumoniae* serotypes in Egypt were found to be 6A/B and 19F. Our collection of isolates was isolated from different specimens representing different diseases caused by *S. pneumoniae*. Most isolates exhibited high rates of resistance to various classes of antibiotics. Molecular typing can be used to identify and confirm the different predominant serotypes of *S. pneumoniae*. Both the virulence factors *autolysin* (*lytA*) and *pneumococcal surface antigen A* (*psaA*) genes are more sensitive than *pneumolysin* (*ply*) gene for *S. pneumoniae* identification. This work demonstrates the importance of constantly monitoring the prevalent serotypes in any region to modulate the components of the used vaccines. This will aid in the development of more effective vaccines that would help elevate the burden of such disease around the world.

Acknowledgments

We would like to thank all staff members of El-Borg private laboratories through its various branches in the greater Cairo area for their assistance in collecting the isolates. Also, we would like to thank all members of the microbiology department at the national organization for drug control and research for their continuous support.

Footnotes

Authors' Contribution: Rehab H Bahy conducted all practical experiments and drafted the manuscript, Hayam M Hamouda supervised the experimental design and analyzed the results. Amal S Shahat did part of the practical experiments and helped in analyzing results. Aymen S Yassin supervised the experimental design analyzed the results and wrote the manuscript in its final form. Magdy A Amin conceived the idea, supervised and directed the whole project.

Funding/Support: Support from national organization for drug control and research (NODCAR), Giza, 12561, Egypt.

References

1. Bogaert D, Hermans PW, Adrian PV, Rumke HC, de Groot R. Pneumococcal vaccines: an update on current strategies. *Vaccine*. 2004;22(17-18):2209-20. doi: [10.1016/j.vaccine.2003.11.038](https://doi.org/10.1016/j.vaccine.2003.11.038). [PubMed: [15149779](https://pubmed.ncbi.nlm.nih.gov/15149779/)].
2. Wasfy MO, Pimentel G, Abdel-Maksoud M, Russell KL, Barrozo CP, Klena JD, et al. Antimicrobial susceptibility and serotype distribution of *Streptococcus pneumoniae* causing meningitis in Egypt, 1998-2003. *J Antimicrob Chemother*. 2005;55(6):958-64. doi: [10.1093/jac/dki101](https://doi.org/10.1093/jac/dki101). [PubMed: [15820983](https://pubmed.ncbi.nlm.nih.gov/15820983/)].
3. Shaban L, Siam R. Prevalence and antimicrobial resistance pattern of bacterial meningitis in Egypt. *Ann Clin Microbiol Antimicrob*. 2009;8:26. doi: [10.1186/1476-0711-8-26](https://doi.org/10.1186/1476-0711-8-26). [PubMed: [19778428](https://pubmed.ncbi.nlm.nih.gov/19778428/)].
4. Afifi S, Wasfy MO, Azab MA, Youssef FG, Pimentel G, Graham TW, et al. Laboratory-based surveillance of patients with bacterial meningitis in Egypt (1998-2004). *Eur J Clin Microbiol Infect Dis*. 2007;26(5):331-40. doi: [10.1007/s10096-007-0280-x](https://doi.org/10.1007/s10096-007-0280-x). [PubMed: [17404766](https://pubmed.ncbi.nlm.nih.gov/17404766/)].
5. Billal DS, Hotomi M, Tasnim S, Fujihara K, Yamanaka N. Evaluation of serotypes of *Streptococcus pneumoniae* isolated from otitis media patients by multiplex polymerase chain reaction. *ORL J Otorhinolaryngol Relat Spec*. 2006;68(3):135-8. doi: [10.1159/000091275](https://doi.org/10.1159/000091275). [PubMed: [16449822](https://pubmed.ncbi.nlm.nih.gov/16449822/)].
6. Brito DA, Ramirez M, de Lencastre H. Serotyping *Streptococcus pneumoniae* by multiplex PCR. *J Clin Microbiol*. 2003;41(6):2378-84. [PubMed: [12791852](https://pubmed.ncbi.nlm.nih.gov/12791852/)].
7. Kong F, Gilbert GL. Using *cpsA-cpsB* sequence polymorphisms and serotype/group-specific PCR to predict 51 *Streptococcus pneumoniae* capsular serotypes. *J Med Microbiol*. 2003;52(Pt 12):1047-58. doi: [10.1099/jmm.0.05277-0](https://doi.org/10.1099/jmm.0.05277-0). [PubMed: [14614062](https://pubmed.ncbi.nlm.nih.gov/14614062/)].
8. Kong F, Wang W, Tao J, Wang L, Wang Q, Sabananthan A, et al. A molecular-capsular-type prediction system for 90 *Streptococcus pneumoniae* serotypes using partial *cpsA-cpsB* sequencing and *wzy*- or *wzx*-specific PCR. *J Med Microbiol*. 2005;54(Pt 4):351-6. doi: [10.1099/jmm.0.45924-0](https://doi.org/10.1099/jmm.0.45924-0). [PubMed: [15770019](https://pubmed.ncbi.nlm.nih.gov/15770019/)].
9. Lawrence ER, Griffiths DB, Martin SA, George RC, Hall LM. Evaluation of semiautomated multiplex PCR assay for determination of *Streptococcus pneumoniae* serotypes and serogroups. *J Clin Microbiol*. 2003;41(2):601-7. [PubMed: [12574253](https://pubmed.ncbi.nlm.nih.gov/12574253/)].
10. O'Halloran D M, Cafferkey MT. Multiplex PCR for identification of seven *Streptococcus pneumoniae* serotypes targeted by a 7-valent conjugate vaccine. *J Clin Microbiol*. 2005;43(7):3487-90. doi: [10.1128/JCM.43.7.3487-3490.2005](https://doi.org/10.1128/JCM.43.7.3487-3490.2005). [PubMed: [16000486](https://pubmed.ncbi.nlm.nih.gov/16000486/)].
11. Park IH, Park S, Hollingshead SK, Nahm MH. Genetic basis for the new pneumococcal serotype, 6C. *Infect Immun*. 2007;75(9):4482-9. doi: [10.1128/IAI.00510-07](https://doi.org/10.1128/IAI.00510-07). [PubMed: [17576753](https://pubmed.ncbi.nlm.nih.gov/17576753/)].

12. Pai R, Gertz RE, Beall B. Sequential multiplex PCR approach for determining capsular serotypes of *Streptococcus pneumoniae* isolates. *J Clin Microbiol.* 2006;**44**(1):124-31. doi: [10.1128/JCM.44.1.124-131.2006](https://doi.org/10.1128/JCM.44.1.124-131.2006). [PubMed: [16390959](https://pubmed.ncbi.nlm.nih.gov/16390959/)].
13. Ostroff SM, Harrison LH, Khallaf N, Assaad MT, Guirguis NI, Harrington S, et al. Resistance patterns of *Streptococcus pneumoniae* and *Haemophilus influenzae* isolates recovered in Egypt from children with pneumonia. The Antimicrobial Resistance Surveillance Study Group. *Clin Infect Dis.* 1996;**23**(5):1069-74. [PubMed: [8922805](https://pubmed.ncbi.nlm.nih.gov/8922805/)].
14. Girgis NI, Sippel JE, Kilpatrick ME, Sanborn WR, Mikhail IA, Cross E, et al. Meningitis and encephalitis at the Abbassia Fever Hospital, Cairo, Egypt, from 1966 to 1989. *Am J Trop Med Hyg.* 1993;**48**(1):97-107. [PubMed: [8427395](https://pubmed.ncbi.nlm.nih.gov/8427395/)].
15. Youssef FG, El-Sakka H, Azab A, Eloun S, Chapman GD, Ismail T, et al. Etiology, antimicrobial susceptibility profiles, and mortality associated with bacterial meningitis among children in Egypt. *Ann Epidemiol.* 2004;**14**(1):44-8. doi: [10.1016/S1047-2797\(03\)00075-9](https://doi.org/10.1016/S1047-2797(03)00075-9).
16. Gounder PP, Zulz T, Desai S, Stenz F, Rudolph K, Tsang R, et al. Epidemiology of bacterial meningitis in the North American Arctic, 2000-2010. *J Infect.* 2015;**71**(2):179-87. doi: [10.1016/j.jinf.2015.04.001](https://doi.org/10.1016/j.jinf.2015.04.001). [PubMed: [25864638](https://pubmed.ncbi.nlm.nih.gov/25864638/)].
17. Park HK, Lee SJ, Yoon JW, Shin JW, Shin HS, Kook JK, et al. Identification of the *cpsA* gene as a specific marker for the discrimination of *Streptococcus pneumoniae* from viridans group streptococci. *J Med Microbiol.* 2010;**59**(Pt 10):1146-52. doi: [10.1099/jmm.0.017798-0](https://doi.org/10.1099/jmm.0.017798-0). [PubMed: [20616191](https://pubmed.ncbi.nlm.nih.gov/20616191/)].
18. Wayne PA. Performance standards for antimicrobial susceptibility testing. 34. USA: CLSI; 2014.
19. Verhelst R, Kaijalainen T, De Baere T, Verschraegen G, Claeys G, Van Simaey L, et al. Comparison of five genotypic techniques for identification of optochin-resistant pneumococcus-like isolates. *J Clin Microbiol.* 2003;**41**(8):3521-5. [PubMed: [12904349](https://pubmed.ncbi.nlm.nih.gov/12904349/)].
20. Walker JA, Allen RL, Falmagne P, Johnson MK, Boulnois GJ. Molecular cloning, characterization, and complete nucleotide sequence of the gene for pneumolysin, the sulfhydryl-activated toxin of *Streptococcus pneumoniae*. *Infect Immun.* 1987;**55**(5):1184-9. [PubMed: [3552992](https://pubmed.ncbi.nlm.nih.gov/3552992/)].
21. Salo P, Ortvist A, Leinonen M. Diagnosis of bacteremic pneumococcal pneumonia by amplification of pneumolysin gene fragment in serum. *J Infect Dis.* 1995;**171**(2):479-82. [PubMed: [7844395](https://pubmed.ncbi.nlm.nih.gov/7844395/)].
22. McAvin JC, Reilly PA, Roudabush RM, Barnes WJ, Salmen A, Jackson GW, et al. Sensitive and specific method for rapid identification of *Streptococcus pneumoniae* using real-time fluorescence PCR. *J Clin Microbiol.* 2001;**39**(10):3446-51. doi: [10.1128/JCM.39.10.3446-3451.2001](https://doi.org/10.1128/JCM.39.10.3446-3451.2001). [PubMed: [11574554](https://pubmed.ncbi.nlm.nih.gov/11574554/)].
23. Sampson JS, Furlow Z, Whitney AM, Williams D, Facklam R, Carlone GM. Limited diversity of *Streptococcus pneumoniae* *psaA* among pneumococcal vaccine serotypes. *Infect Immun.* 1997;**65**(5):1967-71. [PubMed: [9125591](https://pubmed.ncbi.nlm.nih.gov/9125591/)].
24. Morrison KE, Lake D, Crook J, Carlone GM, Ades E, Facklam R, et al. Confirmation of *psaA* in all 90 serotypes of *Streptococcus pneumoniae* by PCR and potential of this assay for identification and diagnosis. *J Clin Microbiol.* 2000;**38**(1):434-7. [PubMed: [10618136](https://pubmed.ncbi.nlm.nih.gov/10618136/)].
25. Tsai HY, Hsueh PR, Teng LJ, Lee PI, Huang LM, Lee CY, et al. Bacteremic pneumonia caused by a single clone of *Streptococcus pneumoniae* with different optochin susceptibilities. *J Clin Microbiol.* 2000;**38**(1):458-9. [PubMed: [10618143](https://pubmed.ncbi.nlm.nih.gov/10618143/)].
26. Pikis A, Campos JM, Rodriguez WJ, Keith JM. Optochin resistance in *Streptococcus pneumoniae*: mechanism, significance, and clinical implications. *J Infect Dis.* 2001;**184**(5):582-90. doi: [10.1086/322803](https://doi.org/10.1086/322803). [PubMed: [11474432](https://pubmed.ncbi.nlm.nih.gov/11474432/)].
27. El-Antably F. M., Abdalla S., Hosney A. M., El-Hadidy G. S. . Phenotypic and gene-technological methods for the identification of clinically isolated *Streptococcus pneumoniae* from Egyptian children. *J Am Sci.* 2010;**12**:1715-9.
28. Kellogg JA, Bankert DA, Elder CJ, Gibbs JL, Smith MC. Identification of *Streptococcus pneumoniae* revisited. *J Clin Microbiol.* 2001;**39**(9):3373-5. [PubMed: [11526182](https://pubmed.ncbi.nlm.nih.gov/11526182/)].
29. Corless CE, Guiver M, Borrow R, Edwards-Jones V, Fox AJ, Kaczmarek EB. Simultaneous detection of *Neisseria meningitidis*, *Haemophilus influenzae*, and *Streptococcus pneumoniae* in suspected cases of meningitis and septicemia using real-time PCR. *J Clin Microbiol.* 2001;**39**(4):1553-8. doi: [10.1128/JCM.39.4.1553-1558.2001](https://doi.org/10.1128/JCM.39.4.1553-1558.2001). [PubMed: [11283086](https://pubmed.ncbi.nlm.nih.gov/11283086/)].
30. Whatmore AM, Eustratiou A, Pickerill AP, Broughton K, Woodard G, Sturgeon D, et al. Genetic relationships between clinical isolates of *Streptococcus pneumoniae*, *Streptococcus oralis*, and *Streptococcus mitis*: characterization of "Atypical" pneumococci and organisms allied to *S. mitis* harboring *S. pneumoniae* virulence factor-encoding genes. *Infect Immun.* 2000;**68**(3):1374-82. [PubMed: [10678950](https://pubmed.ncbi.nlm.nih.gov/10678950/)].
31. Seki M, Yamashita Y, Torigoe H, Tsuda H, Sato S, Maeno M. Loop-mediated isothermal amplification method targeting the *lytA* gene for detection of *Streptococcus pneumoniae*. *J Clin Microbiol.* 2005;**43**(4):1581-6. doi: [10.1128/JCM.43.4.1581-1586.2005](https://doi.org/10.1128/JCM.43.4.1581-1586.2005). [PubMed: [15814969](https://pubmed.ncbi.nlm.nih.gov/15814969/)].
32. El Kholly A, Baseem H, Hall GS, Procop GW, Longworth DL. Antimicrobial resistance in Cairo, Egypt 1999-2000: a survey of five hospitals. *J Antimicrob Chemother.* 2003;**51**(3):625-30. [PubMed: [12615864](https://pubmed.ncbi.nlm.nih.gov/12615864/)].
33. Guirguis N, Hafez K, El Kholly MA, Robbins JB, Gotschlich EC. Bacterial meningitis in Egypt: analysis of CSF isolates from hospital patients in Cairo, 1977-78. *Bull World Health Organ.* 1983;**61**(3):517-24. [PubMed: [6411374](https://pubmed.ncbi.nlm.nih.gov/6411374/)].
34. Guirguis NI, Helmy MF, Mohamed MR, Ali RH. A suggested vaccine formulation for the control of pneumococcal meningitis in Egypt. *J Egypt Public Health Assoc.* 1990;**65**(3-4):291-303. [PubMed: [2133903](https://pubmed.ncbi.nlm.nih.gov/2133903/)].
35. Carvalho Mda G, Tondella ML, McCaustland K, Weidlich L, McGee L, Mayer LW, et al. Evaluation and improvement of real-time PCR assays targeting *lytA*, *ply*, and *psaA* genes for detection of pneumococcal DNA. *J Clin Microbiol.* 2007;**45**(8):2460-6. doi: [10.1128/JCM.02498-06](https://doi.org/10.1128/JCM.02498-06). [PubMed: [17537936](https://pubmed.ncbi.nlm.nih.gov/17537936/)].
36. Rajam G, Anderton JM, Carlone GM, Sampson JS, Ades EW. Pneumococcal surface adhesin A (PsaA): a review. *Crit Rev Microbiol.* 2008;**34**(3-4):131-42. doi: [10.1080/10408410802275352](https://doi.org/10.1080/10408410802275352). [PubMed: [18728990](https://pubmed.ncbi.nlm.nih.gov/18728990/)].